TECTONIC THERAPEUTIC INC
TECXNASDAQTrading Snapshot
- Day Range
- $20.36 – $21.44
- 52-Week Range
- $15.52 – $39.53
- Volume (shares)
- 139,590
- Avg Volume (shares)
- —
- Shares Outstanding
- 19.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-4.56
- Dividend Yield
- —
- Dilution (1yr)
- +23.9%
TECTONIC THERAPEUTIC INC
TECX
StockOtter · stockotter.spaceAbout TECTONIC THERAPEUTIC INC
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled receptors (GPCRs). The company leverages its proprietary GEODe technology platform to facilitate the discovery and development of these GPCR-targeted medicines. Its robust pipeline includes an RXFP1 agonist, currently undergoing Phase 1a and 1b clinical trials for the treatment of heart failure with preserved ejection fraction. Additional programs encompass a GPCR antagonist addressing hereditary hemorrhagic telangiectasia, a bi-functional GPCR modulator aimed at fibrosis, and various other GPCR modulators. Tectonic Therapeutic, Inc. is situated in Watertown, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates
Tectonic Therapeutic, Inc. (TECX) – What Are Researchers Thinking About This Stock?
Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten analysts that are presently covering the company, Marketbeat.com reports. One investment analyst ha
Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)
U.S. FDA has granted Fast Track designation for TX2100 in HHT and cleared the Investigational New Drug (IND) application for the TX2100 Phase 1b clinical trial in HHT patients in the U.S. TX2100 Phase 1a clinical trial t
Tectonic Therapeutic, Inc. (NASDAQ:TECX) Stock Has Average Price Target of $77.25 According to Analysts
Tectonic Therapeutic, Inc. (NASDAQ: TECX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the
Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference
WATERTOWN, Mass., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and ant
Tectonic Therapeutic: Competitor Data Strengthens The TX45 Bull Case
Tectonic Therapeutic offers a validated, severity-enriched trial design for TX45 in CpcPH-HFpEF, with external support from Merck's CADENCE results. Phase 1b TX45 data show promising hemodynamic effects, and the company'
Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights
Enrollment completed in TX45 APEX Phase 2 clinical trial in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (“PH-HFpEF”) with topline results anticipated in early Q1 20